Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
9.36M
-
Number of holders
-
33
-
Total 13F shares, excl. options
-
633K
-
Shares change
-
-429K
-
Total reported value, excl. options
-
$3.21M
-
Value change
-
-$2.6M
-
Number of buys
-
10
-
Number of sells
-
-20
-
Price
-
$5.07
Significant Holders of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q1 2025
42 filings reported holding CARA - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 633K shares
of 9.36M outstanding shares and own 6.77% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (168K shares), FARALLON CAPITAL MANAGEMENT LLC (130K shares), RENAISSANCE TECHNOLOGIES LLC (88.5K shares), BlackRock, Inc. (61.9K shares), TWO SIGMA ADVISERS, LP (49.2K shares), GEODE CAPITAL MANAGEMENT, LLC (39.4K shares), BANK OF AMERICA CORP /DE/ (27K shares), UBS Group AG (19.1K shares), MILLENNIUM MANAGEMENT LLC (17.4K shares), and STATE STREET CORP (14.9K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.